Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Last Updated
In the Matter of Mylan Inc., a corporation; Agila Specialties Global Pte.Limited, a corporation; Agila Specialties Private Limited, a corporation; and Strides Arcolab Limited, a corporation
FTC Matter/File Number
131 0112
Docket Number
C-4413
Enforcement Type
Part 2 Consents

Case Summary

Under a settlement with th FTC, Mylan, Inc., and Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. (collectively, Agila)  divested 11 generic injectable drugs as a condition of allowing Mylan’s proposed acquisition of Agila from Strides Arcolab Ltd. (Strides). According to the complaint, in each of these 11 markets, Mylan and Agila are two of only a limited number of current or likely future competitors. The number of suppliers in generic pharmaceutical markets matters because prices generally decrease as the number of competing generic suppliers increases. In addition, the injectable generic products of concern are highly susceptible to supply disruptions caused by the inherent difficulties of producing sterile liquid drugs.

Case Timeline